Profile data is unavailable for this security.
About the company
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
- Revenue in AUD (TTM)16.23m
- Net income in AUD-40.56m
- Incorporated2020
- Employees87.00
- LocationAVITA Medical Inc28159 Avenue Stanford, Suite 220VALENCIA 91355United StatesUSA
- Phone+1 (661) 367-9170
- Websitehttps://www.avitamedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cogstate Ltd | 66.78m | 8.38m | 171.02m | 61.00 | 20.41 | 2.69 | 13.58 | 2.56 | 0.0485 | 0.0485 | 0.3858 | 0.3685 | 0.7762 | -- | 4.96 | -- | 9.74 | 8.45 | 12.51 | 12.30 | 55.96 | 53.13 | 12.55 | 10.75 | -- | -- | 0.0162 | 0.00 | 7.36 | 14.72 | 52.75 | -- | -5.00 | -- |
| Dimerix Ltd | 583.48k | -17.08m | 181.30m | 0.00 | -- | 9.83 | -- | 310.71 | -0.0373 | -0.0373 | 0.0013 | 0.0331 | 0.0234 | -- | 0.0612 | -- | -68.53 | -71.97 | -98.37 | -113.16 | -- | -- | -2,926.42 | -8,332.83 | -- | -- | 0.0082 | -- | 1,485.97 | 100.27 | -23.71 | -- | 17.99 | -- |
| Arovella Therapeutics Ltd | 155.73k | -8.75m | 190.12m | 14.00 | -- | 16.84 | -- | 1,220.86 | -0.0093 | -0.0093 | 0.0002 | 0.0107 | 0.0166 | -- | 30.42 | -- | -93.26 | -78.61 | -116.36 | -96.29 | 100.00 | 51.81 | -5,616.16 | -2,126.97 | -- | -1,012.45 | 0.00 | -- | -64.27 | -34.07 | 14.10 | -- | -37.76 | -- |
| Race Oncology Ltd | 832.58k | -13.82m | 243.78m | -- | -- | 13.30 | -- | 292.80 | -0.0839 | -0.0839 | 0.0051 | 0.1075 | 0.0355 | -- | 0.9201 | -- | -58.97 | -46.49 | -63.04 | -48.68 | -- | -- | -1,659.82 | -2,995.74 | -- | -- | 0.00 | -- | 40.68 | 116.86 | -39.26 | -- | -- | -- |
| Imugene Ltd | 0.00 | -149.68m | 275.22m | 0.00 | -- | 2.29 | -- | -- | -0.0211 | -0.0211 | 0.00 | 0.0162 | 0.00 | -- | -- | -- | -85.91 | -44.42 | -95.62 | -47.46 | -- | -- | -- | -- | -- | -- | 0.0053 | -- | -- | -- | -294.78 | -- | 136.28 | -- |
| Immutep Ltd | 119.62k | -42.72m | 414.55m | 19.00 | -- | 2.20 | -- | 3,465.57 | -0.0353 | -0.0353 | 0.0001 | 0.1293 | 0.0007 | -- | 0.655 | -- | -24.48 | -31.68 | -25.99 | -33.91 | -- | -- | -35,710.27 | -1,829.94 | -- | -- | 0.0083 | -- | -37.61 | -54.35 | -7.07 | -- | 86.40 | -- |
| AVITA Medical Inc | 16.23m | -40.56m | 526.13m | 87.00 | -- | 339.32 | -- | 32.42 | -0.0288 | -0.0288 | 0.0114 | 0.0117 | 0.1882 | 2.86 | 5.89 | 186,506.20 | -47.05 | -121.83 | -51.04 | -152.54 | 78.72 | 73.46 | -249.98 | -633.80 | 15.22 | -197.63 | 0.0301 | -- | 543.96 | 24.92 | -112.85 | -- | 88.43 | -- |
| Opthea Ltd | 191.71k | -338.68m | 769.43m | 5.00 | -- | -- | -- | 4,013.50 | -0.5313 | -0.5313 | 0.0003 | -0.1068 | 0.0009 | -- | 0.0136 | -- | -153.25 | -112.75 | -215.25 | -134.33 | 100.00 | -- | -176,660.10 | -113,428.10 | -- | -5.08 | 1.61 | -- | 15.00 | 1.86 | -54.53 | -- | 20.99 | -- |
| Mesoblast Ltd | 9.08m | -135.25m | 1.70bn | 73.00 | -- | 2.29 | -- | 186.82 | -0.1347 | -0.1347 | 0.0092 | 0.6473 | 0.0088 | -- | 3.21 | 124,326.00 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -42.32m | 1.91bn | -- | -- | 12.72 | -- | -- | -0.1541 | -0.1541 | 0.00 | 0.4694 | 0.00 | -- | -- | -- | -36.56 | -- | -39.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.03 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sandhurst Trustees Ltd.as of 31 Jan 2024 | 278.70k | 0.21% |
